Conversion to Sirolimus in Pediatric Renal Transplantation Recipients
作者： C.D. Garcia , V.B. Bittencourt , A.B. Alves , V.D. Garcia , A. Tumelero
DOI: 10.1016/J.TRANSPROCEED.2006.06.063
关键词:
摘要: We retrospectively evaluated the efficacy and safety of sirolimus (SRL) in 16 pediatric renal transplant recipients, who were 9.4 ± 4.1 years age when they first received SRL. The indications for SRL therapy rescue from steroid-resistant acute rejection (31.3%), neoplasia diabetes (12.5%), polyomavirus-associated nephropathy (6.3%), chronic allograft dysfunction calcineurin inhibitor nephrotoxicity hemolytic uremic syndrome (6.3%). Mean follow-up after switch to was 17.7 15 months. final immunosuppression CNI + prednisone (PRED) five patients, PRED six, mycophenolate mofetil (MMF) four, MMF one. use these selected recipients successful, except creatinine high at moment conversion. Further studies are necessary assess benificial outcomes versus adverse events among population receiving immunosuppression.
elsevier.com
sci-hub.se 参考文章(26)
Ravi Rao, Jan Buckner, Jann Sarkaria, Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents Current Cancer Drug Targets. ,vol. 4, pp. 621- 635 ,(2004) , 10.2174/1568009043332718
Viorica Bumbea, Nassim Kamar, David Ribes, Laure Esposito, Anne Modesto, Joelle Guitard, Ghassan Nasou, Dominique Durand, Lionel Rostaing, Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus Nephrology Dialysis Transplantation. ,vol. 20, pp. 2517- 2523 ,(2005) , 10.1093/NDT/GFH957
Barry D Kahan, Sirolimus-based immunosuppression: present state of the art. Journal of Nephrology. ,(2004)
First Mr, Tacrolimus based immunosuppression. Journal of Nephrology. ,(2004)
K.-L. Liu, S.-H. Chu, Y.-J. Chiang, C.-T. Wu, Y. Chen, Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: An initial experience in Taiwan Congress of the Asian Society of Transplantation (CAST). ,vol. 36, pp. 2051- 2052 ,(2004) , 10.1016/J.TRANSPROCEED.2004.08.095
Jeffrey S. Zaltzman, Ramesh Prasad, Kathy Chun, Serge Jothy, Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus Nephrology Dialysis Transplantation. ,vol. 20, pp. 1748- 1751 ,(2005) , 10.1093/NDT/GFH884
Emmanuel Mah??, Emmanuel Morelon, Sophie Lechaton, Kim-Hanh Le Quan Sang, Rafik Mansouri, Marie-Fran??oise Ducasse, Marie-France Mamzer-Bruneel, Yves de Prost, Henri Kreis, Christine Bodemer, Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation. ,vol. 79, pp. 476- 482 ,(2005) , 10.1097/01.TP.0000151630.25127.3A
William F Keane, Garabed Eknoyan, None, Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation American Journal of Kidney Diseases. ,vol. 33, pp. 1004- 1010 ,(1999) , 10.1016/S0272-6386(99)70442-7
Shih-Chieh J. Chueh, Barry D. Kahan, Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1 Transplantation. ,vol. 76, pp. 375- 382 ,(2003) , 10.1097/01.TP.0000074310.40484.94
J.D Morrisett, G Abdel-Fattah, B.D Kahan, Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients 10 Years of mTOR Inhibitor Therapy. Symposium. ,vol. 35, pp. 143- 150 ,(2003) , 10.1016/S0041-1345(03)00233-1